Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Table 4 Multivariate analysis: overall survival and local-regional progression-free survival

Variable	OS			LRPFS
	p	HR	95% CI	p	HR	95% CI
Gender (Female vs. Male)	0.288	0.802	0.534-1.205	0.278	0.753	0.450-1.258
Age (years) (≥65 vs. <65)	0.297	0.817	0.558-1.195	0.248	0.760	0.477-1.211
Pathological type (Non-squamous vs. Squamous)	0.106	1.364	0.936-1.988	0.494	1.184	0.729-1.924
T stage (T3-T4 vs. T1-T2)	0.728	1.067	0.740-1.540	0.702	1.097	0.684-1.759
Distant metastatic lesions (No radiotherapy vs. Radiotherapy)	0.682	1.083	0.740-1.584	0.652	1.118	0.689-1.812
Intrathoracic primary tumors (No response vs. Response)	0.592	1.124	0.733-1.724	0.581	1.188	0.644-2.190
GTV (<175 cm³ vs. ≥175 cm³)	0.008	1.747	1.153-2.646	0.003	2.321	1.336-4.032
Post-treatment KPS (Decreased ≥10 vs. Stable or increased ≥10)	0.000	6.282	3.568-11.058	0.000	8.038	3.769-17.140
N stage (N2-N3vs. N0-N1)	0.059	1.636	0.981-2.727	0.234	1.438	0.790-2.615
Chemotherapy cycles (2–3 vs. 4–5)	0.035	1.484	1.028-2.144	0.128	1.431	0.903-2.268
Intrathoracic primary tumors radiation doses (<63Gy vs. ≥63Gy)	0.057	1.433	0.989-2.075	0.051	1.562	0.999-2.443

ISSN: 1471-2407